Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
出版年份 2015 全文链接
标题
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients
作者
关键词
c-MET, Epidermal growth factor receptor, Gastric cancer, Gastroesophageal junction cancer, Human epidermal growth factor receptor 2
出版物
Gastric Cancer
Volume 19, Issue 1, Pages 183-191
出版商
Springer Nature
发表日期
2015-02-17
DOI
10.1007/s10120-015-0471-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).
- (2017) Hansjochen Wilke et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- METamplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy
- (2013) Xin An et al. CANCER
- Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population
- (2013) Masaki Aizawa et al. Gastric Cancer
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2013) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
- (2013) Sang Y Ha et al. MODERN PATHOLOGY
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
- (2012) M. Terashima et al. CLINICAL CANCER RESEARCH
- The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays
- (2012) Kambiz Sotoudeh et al. Diagnostic Pathology
- Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
- (2012) Kohei Shitara et al. Gastric Cancer
- Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma
- (2012) Yin Li et al. JOURNAL OF SURGICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
- (2009) Sumithra J. Mandrekar et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer
- (2008) M. Hayashi et al. CLINICAL CANCER RESEARCH
- Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer
- (2008) J. Matsubara et al. CLINICAL CANCER RESEARCH
- EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
- (2008) M A Kim et al. HISTOPATHOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation